Independent. No paid rankings. Our evidence grades are never for sale. Where a cosmetic or skincare product passes our review, we may link to it with a disclosed affiliate link. Reviewed weekly Editorial policy Newsletter

Home›Explore peptides›Argireline

Argireline

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 11 September 2026Funding No vendor payment

A peptide marketed as a topical alternative to Botox, with a genuinely mixed evidence record. An early study and one randomised trial reported benefits; the most recent independent evaluation found no measurable effect at all.

Evidence grade B: what kinds of studies support the claims on this page, with limits. It is not a verdict on any product. How we grade

On this page

  1. What it actually is
  2. What the evidence supports
  3. Why we're not grading this higher
  4. How long it takes
  5. What it does not do
  6. What to look for

In brief

Should you care? Cautiously, and with real caveats. The mechanism is genuine and well characterised, and an early trial reported benefits — but the most recent independent evaluation we could find reported no measurable effect at all.3 This is a mixed evidence picture, not a settled one.

The short version

  • What it does: works like a very mild, topical version of a muscle-relaxing injectable — it does not paralyse muscle, it modestly reduces the signal.
  • Evidence: grade B — a real mechanism and one positive randomised trial, offset by an independent evaluation finding no effect. Treat any single positive study here with real caution.
  • What it won't do: replace an injectable, guarantee a result, or work at the low doses most drugstore products actually use.

What it actually is

Argireline is the trade name for acetyl hexapeptide-8, a synthetic peptide designed to mimic part of a protein involved in the signalling that tells facial muscles to contract. The idea, sometimes called "Botox in a bottle" in marketing copy, is that it modestly dampens that signal at the skin's surface rather than blocking it at the nerve the way an injectable does.

The comparison to injectables is a considerable overstatement of the effect size, even where the underlying mechanism is genuine. It’s classed as a neurotransmitter-inhibitor peptide — a different job entirely from signal and carrier peptides.

What the evidence supports

Argireline was first characterised in a 2002 paper (Blanes-Mira et al., International Journal of Cosmetic Science), combining laboratory evidence that it dose-dependently inhibits neurotransmitter release with a small, uncontrolled human proof-of-concept.1 A 2013 randomised trial in 60 subjects (Wang et al.) reported a positive result at 4 weeks — 48.9% of the treated group saw subjective improvement versus none of the placebo group.2 But a small 2023 independent study (Henseler et al., 19 women, 4 weeks) testing acetyl hexapeptide-8 added to a hyaluronic-acid serum found no additional effect over the serum alone.3 That is a real null result, though from a small add-on comparison, not a head-to-head trial against a true placebo — worth weighing alongside the positive trial rather than treating as the final word either way. A separate small, uncontrolled 2020 study of a 10% gel-cream in 26 patients reported improvements in hydration, elasticity and sebum measures, but it had no control group and was not designed to isolate a wrinkle-depth effect.4

Why we're not grading this higher

A null result is a real data point, not something to explain away

A small, independent study finding no added effect is meaningful evidence in its own right — it is not automatically overridden by an earlier positive study, even though it was a smaller add-on comparison rather than a large head-to-head trial. Combined with most commercial products using an undisclosed, likely lower concentration than any of the trials above, the honest summary is: plausible mechanism, inconsistent evidence. Worth trying at a clearly stated 10%, with modest expectations, not something to rely on.

How long it takes

Published studies in this category run roughly 4 to 12 weeks. Given how mixed the evidence is, judge conservatively: if you see nothing after 8 weeks at a properly disclosed 10% concentration, that is a reasonable, evidence-consistent outcome — not necessarily a sign you are doing something wrong.

What it does not do

Claims the evidence does not carry

  • Replace an injectable. Even taking the positive studies at face value, the effect size is a fraction of what a neuromodulator injection achieves. "Botox in a bottle" is marketing language, not a clinical equivalence.
  • Guarantee a visible result. A credible independent trial found none at all — treat any outcome here as a possibility, not an expectation.
  • Work at typical retail concentrations. Without a stated percentage, assume you are not getting the tested dose.
  • Address static wrinkles (lines present at rest, from lost collagen and volume) the way it may soften dynamic expression lines. Those are different problems.

What to look for

  • A stated percentage, ideally at the 10% most of the trial data actually covers.
  • Targeting for expression lines specifically — forehead, crow’s feet — rather than a general anti-ageing claim.
  • Realistic marketing language. A brand leaning hard on "Botox alternative" is telling you more about its marketing than its formulation, and definitely more than the evidence supports.

What you can do next

References

  1. Blanes-Mira C. et al. (2002), International Journal of Cosmetic Science — original characterisation of acetyl hexapeptide-8, combining laboratory neurotransmitter-inhibition data with a small uncontrolled human proof-of-concept.
  2. Wang Y, Wang M, Xiao S, et al. (2013), "The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects," American Journal of Clinical Dermatology 14(2):147–153. 60 subjects (3:1 acetyl hexapeptide-8 to placebo), peri-orbital wrinkles, 4 weeks. Subjective improvement reported by 48.9% of the treated group versus 0% of placebo; objective surface roughness also decreased. DOI: 10.1007/s40257-013-0009-9
  3. Henseler H. et al. (2023), "Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia® Complexion Analysis camera system for objective skin analysis," GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW 12:Doc09. Split-face, 19 women, 4 weeks, comparing a hyaluronic-acid serum with and without acetyl hexapeptide-8 — found no significant additional wrinkle reduction from adding it. A small independent study, not a large trial; treat the null result as real but not the final word. PMID: 38024099
  4. Palmieri B, Noviello A, Corazzari V, Garelli A, Vadalà M (2020), "Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8," La Clinica Terapeutica 171(6):e539–e548. Retrospective, uncontrolled study of a 10% acetyl hexapeptide-8 gel-cream in 26 oncology/dermatology patients; measured hydration, elasticity and sebum — safety-focused, not designed to isolate an efficacy result. DOI: 10.7417/CT.2020.2270